{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"11.1","value":"4.6"},{"groupId":"OG001","lowerLimit":"6.0","upperLimit":"12.3","value":"8.3"},{"comment":"Could not be estimated due to the low number of events","groupId":"OG002","lowerLimit":"11.3","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"67"}],"units":"Participants"}],"description":"Time to Progression is defined as the time from the start of treatment to IRC-determined disease progression. Patients who were lost to follow-up prior to documentation of disease progression, or who died before documentation of disease progression or who were alive and did not have documentation of disease progression before the data analysis cut-off date were censored at the last disease assessment.\n\nMedian TTP was estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants previously treated with bortezomib received carfilzomib 20 mg/m² intravenous (IV) injection on Days 1, 2, 8, 9, 15, and 16, in 28-day treatment cycles for a maximum of 12 cycles.","id":"OG000","title":"Part 1: Carfilzomib 20 mg/m²"},{"description":"Participants not previously treated with bortezomib received carfilzomib 20 mg/m² IV injection on Days 1, 2, 8, 9, 15, and 16, in 28-day treatment cycles for a maximum of 12 cycles.","id":"OG001","title":"Part 2: Carfilzomib 20 mg/m²"},{"description":"Participants not previously treated with bortezomib received carfilzomib 20 mg/m² IV on Days 1, 2, 8, 9, 15, and 16 of Cycle 1. If all doses were well-tolerated the dose was escalated to 27 mg/m² IV on Days 1, 2, 8, 9, 15, and 16 for subsequent cycles, for up to 12 cycles.","id":"OG002","title":"Part 2: Carfilzomib 20/27 mg/m²"}],"paramType":"MEDIAN","populationDescription":"Response Evaluable Population","reportingStatus":"POSTED","timeFrame":"Patients were followed for up to 2 years after study discontinuation. The data cutoff for the analysis is 30 November 2010 for Part 1 and 22 April 2011 for Part 2. Median follow-up time was 13.4 months for Part 1 and 11.5 months in Part 2.","title":"Time to Progression (TTP)","type":"SECONDARY","unitOfMeasure":"months"}